Recruiting NA INTERVENTIONAL 2-arm NCT06596954

Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

Lymphocyte-sparing Thoracic Radiotherapy vs Conventional Radiotherapy for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Therapy: an Open Label, Randomized Controlled Trial

Sponsor: Ruijin Hospital

Conditions Esophageal Squamous Cell Cancer

Interventions conventional radiotherapy lymphocyte-sparing radiotherapy

Updated 2 times since 2024 Last updated: Aug 5, 2025 Started: Jun 30, 2024 Primary completion: Jun 30, 2027 Completion: Dec 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06596954, this NA trial focuses on Esophageal Squamous Cell Cancer and remains actively recruiting participants. Sponsored by Ruijin Hospital, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA
Oct 2024 — Sep 2025 [monthly]

Recruiting NA

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China